Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15815 articles
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
Glutathione S-transferase P1 knockdown selectively influenced cisplatin and carboplatin chemosensitivity.
»
05/07/14
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Treatment with ipilimumab plus sargramostim vs ipilimumab alone resulted in longer OS.
»
11/05/14
Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer.
High immunoreactivity of nuclear CXCR4 in gastric cancer suggests that CXCL12 binds to its unique receptor CXCR4 at the membrane.
»
11/05/14
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Presence of the mutation was associated with shorter patient survival.
»
11/27/13
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Combined treatment was safe and well-tolerated but feasibility was marginal.
»
02/08/14
Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway.
Increased cell proliferation rate induced by Mst1 down-regulation was partially abolished by down-regulation of AKT1.
»
06/05/14
Cyclopamine decreased the expression of sonic hedgehog and its downstream genes in colon cancer stem cells.
Cyclopamine treatment could down-regulate the expression of stemness markers and shh downstream genes.
»
11/05/14
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Antiprogestins are therapeutic tools that selectively inhibit PRA-overexpressing tumors.
»
02/05/14
A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
High-hMAPK-microRNA status significantly correlated with ER-negativity.
»
11/06/14
Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.
MKP1 serves as a major downstream effector in the HER2-activated RAF-MEK-ERK pathway.
»
11/08/14
< Prev
Next >